BTK and B-cell chronic lymphocytic leukemia: The above cited studies have demonstrated that resistance to novel agents in CLL, especially when caused by acquired BTK and BCL2 mutations, appears to occur rather late in the course of treatment, though some reports show the detection of these mutations as early events [31].